1.Study on dehydroepiandrosteron permeation from Transdermal Therapeutic Systems
Pharmaceutical Journal 2005;0(11):14-16
To study in vitro usability of Transdermal Therapeutic Systems (TTS) dehydroepiandrosteron (DHEA) on pig's ear skin. Results showed that: there was correlation about DHEA permeation between human and pig's ear skin. DHEA permeation speed was linear proportional with square root of time and the DHEA content in TTS. DHEA permeation speed via human skin had linear correlation with permeation speed via pig's ear skin with angular co-efficient 0.74; this showed that pig's ear skin can be used for exploratory research on establishing formulation of transdermal drugs. Pig skins are available material and easy to collect with large amount. However, this result also showed that permeation ability of human skin is lower than pig’s ear skin
Dehydroepiandrosterone
;
Administration, Cutaneous
;
Therapeutics
2.Effect of DHEA Administration Alone or Exercise combined with DHEA before Steroid Treatment on Rat Hindlimb Muscles.
Journal of Korean Academy of Nursing 2009;39(3):321-328
PURPOSE: The purpose of this study was to determine the effect of Dehydroepiandrosterone (DHEA) administration alone or exercise combined with DHEA before steroid treatment on rat hindlimb muscles. METHODS: Male Sprague-Dawley rats were assigned to one of three groups: a steroid group (S, n=10) that had no treatment for 7 days before steroid treatment; a DHEA-steroid group (DS, n=8) that had 0.34 mmol/kg/day DHEA injection once a day for 7 days before steroid treatment and an exercise?steroid group (EDS, n=9) that ran on the treadmill combined with 0.34 mmol/kg/day DHEA injection for 7 days before steroid treatment. At 15 days all rats were anesthetized and soleus, plantaris and gastrocnemius muscles were dissected. Body weight, food intake, muscle weight, myofibillar protein content and cross-sectional area of the dissected muscles were determined. RESULTS: The DS group showed significant increases (p<.05) as compared to the steroid group in body weight, and muscle weight of gastrocnemius muscles. The EDS group showed significant increases (p<.05) as compared to the S group in body weight, muscle weight, myofibrillar protein content, and Type II fiber cross-sectional area of soleus, plantaris and gastrocnemius muscles. CONCLUSION: Exercise combined with DHEA administration before steroid treatment prevents steroid induced muscle atrophy, with exercise combined with DHEA administration being more effective than DHEA administration alone in preventing muscle atrophy.
Animals
;
Body Weight
;
Dehydroepiandrosterone/*administration & dosage
;
Hindlimb
;
Male
;
Muscle Contraction/drug effects
;
Muscle, Skeletal/*drug effects/pathology
;
Muscular Atrophy/chemically induced/*prevention & control
;
*Physical Conditioning, Animal
;
Rats
;
Rats, Sprague-Dawley
;
Steroids/*toxicity
3.Effect of Dehydroepiandrosterone on Affected and Unaffected Hindlimb Muscles in Rats with Neuropathic Pain Induced by Unilateral Peripheral Nerve Injury.
Journal of Korean Academy of Nursing 2009;39(5):632-640
PURPOSE: The purpose of this study was to examine the effect of DHEA (Dehydroepiandrosterone) on muscle weight and Type I and II fiber cross-sectional area of affected and unaffected hindlimb muscles in rats with neuropathic pain induced by unilateral peripheral nerve injury. METHODS: Neuropathic pain was induced by ligation and cutting of the left L5 spinal nerve. Adult male Sprague-Dawley rats were randomly assigned to one of two groups: The DHEA group (n=10) had DHEA injections daily for 14 days, and the Vehicle group (n=10) had vehicle injections daily for 14 days. Withdrawal threshold, body weight, food intake and activity were measured every day. At 15 days all rats were anesthetized and soleus, plantaris and gastrocnemius muscles were dissected from the both hindlimbs. Body weight, food intake, activity, muscle weight and Type I, II fiber cross-sectional area of the dissected muscles were measured. RESULTS: The DHEA group showed significant increases (p<.05), as compared to the vehicle group for muscle weight of the unaffected plantaris, and in Type II fiber cross-sectional area of the gastrocnemius muscle. The DHEA group demonstrated a higher pain threshold than the vehicle group whereas total diet intake and activity score were not significantly different between the two groups. CONCLUSION: DHEA administration for 14 days attenuates unaffected plantaris and gastrocnemius muscle atrophy.
Animals
;
Body Weight
;
Dehydroepiandrosterone/*administration & dosage
;
Disease Models, Animal
;
Eating/drug effects
;
*Hindlimb
;
Male
;
Muscle Fibers, Skeletal/*drug effects/pathology
;
Muscle, Skeletal/drug effects
;
Muscular Atrophy/*drug therapy
;
Pain/etiology
;
Pain Measurement
;
Peripheral Nerves/*injuries
;
Rats
;
Rats, Sprague-Dawley
4.Study of dehydroepiandrosterone retarding atherosclerosis of high cholesterol-fed rabbits.
Heng-hui CHENG ; Zhi-ling QU ; Ying ZHOU ; Zhen-ying BAN ; Xiao-jing HU ; Qiu-rong RUAN
Chinese Journal of Pathology 2007;36(4):263-264
Animals
;
Aorta
;
pathology
;
Atherosclerosis
;
blood
;
etiology
;
metabolism
;
Chemokine CCL2
;
metabolism
;
Cholesterol
;
blood
;
Cholesterol, Dietary
;
administration & dosage
;
Cholesterol, HDL
;
blood
;
Cholesterol, LDL
;
blood
;
Dehydroepiandrosterone
;
pharmacology
;
Diet, Atherogenic
;
Immunohistochemistry
;
Rabbits
;
Random Allocation
;
Triglycerides
;
blood
;
Vascular Cell Adhesion Molecule-1
;
metabolism
5.Anti-mutagenicity activity of dehydroepiandrosterone.
Sun YANG ; Zhaodi FU ; Fang WANG ; Yu CAO ; Rui HAN
Chinese Journal of Oncology 2002;24(2):137-140
OBJECTIVEThe chemopreventive activity and mechanism of dehydroepiandrosterone (DHEA) were studied.
METHODSModel of 7, 12-dimethylbenz (alpha) anthracene (DMBA) induced breast carcinoma in Sprague-Dawley rats, uitra-violet (UV)-induced DNA damage and Salmonella mutation assay were used.
RESULTSIn DMBA-induced rat mammary tumor model, the rats were orally given daily DHEA for 2 weeks before DMBA and continued for 10 weeks after DMBA administration. The results showed significant inhibition of tumor development by DHEA. The incidence of mammary carcinoma also decreased significantly on daily dose of oral 25 mg/kg DHEA with the mean tumor volume per rat also remarkably reduced by 92%. Moreover, 25 mg/kg DHEA treatment could significantly increase the carcinoma latency for about 3.5 weeks as compared with the control. Using polymerase chain reaction (PCR) assay, in vitro 10(-9) mol/L DHEA showed significant inhibitory effect on UV-induced DNA damage by 90%. In Ames test, DHEA was found to decrease DMBA and benzo (alpha) pyrene-induced TA98 and TA100 His(+) revertants markedly and the number of Salmonella clones were significantly reduced by 53.2% and 73.0% on dose of 5 microgram DHEA/plate. It was also shown that in vitro 10(-7) mol/L DHEA could also effectively inhibit the G-6-PDH activity, which might play an important role in its chemoprophylaxis activities.
CONCLUSIONThe results strongly prove that DHEA is a potent cancer chemoprophylaxis agent, which exhibits inhibitory potential on mutation and chemical carcinogen in vivo and in vitro.
9,10-Dimethyl-1,2-benzanthracene ; administration & dosage ; Adjuvants, Immunologic ; pharmacology ; Animals ; Antimutagenic Agents ; pharmacology ; DNA Damage ; drug effects ; Dehydroepiandrosterone ; pharmacology ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Glucosephosphate Dehydrogenase ; antagonists & inhibitors ; metabolism ; Mammary Neoplasms, Experimental ; chemically induced ; prevention & control ; Mutagenicity Tests ; Rats ; Rats, Sprague-Dawley ; Salmonella ; drug effects ; genetics ; Time Factors ; Tumor Cells, Cultured